Jed Pheneger has served as senior director of pharmacology – inflammation, at Inotiv since May 2021 at our Boulder location. His over 20 years of experience in pharmaceutical discovery research provide Inotiv with research expertise in inflammation disease models and assays. From developing research models and assays and presenting at scientific meetings to co-authoring papers and patents, Pheneger has the experience our clients need. His diverse expertise allows Inotiv to offer support to even the most challenging inflammation drug projects.
Pheneger earned his Bachelor of Science in zoology from University of Wyoming, then attended the Health One School of Medical Technology. During this time, he also worked as a research associate at Amgen Boulder, Inc. He then worked as a histotechnologist at Unipath, followed by a medical technology position at Duke University Medical Center. In 2000, he joined BolderPATH as a histotechnologist, which led to a study director position focused on anti-inflammatory projects. He then rose rapidly through the ranks, eventually reaching a research scientist position. In 2003, he started as a research associate at Array Biopharma, eventually reaching a senior research scientist position in 2014. He returned to Bolder BioPATH, ultimately becoming a vice president of research before joining Inotiv. His deep knowledge of research models and inflammation supports all of Inotiv’s anti-inflammation characterization services.